Walvax reports Q3 2025 financials: Profit down 36%, cash flow plunges 85%

Walvax Biotechnology's Q3 2025 financial report indicates a decrease in total assets by RMB 1.47 bn to RMB 13.25 bn from the prior year-end, primarily due to dividend payments and fixed asset investments. The company recorded a net profit attributable to shareholders of RMB 163.44 m, a 36.24% decline year-over-year. Operating cash flow also significantly decreased by 85.75% to RMB 79.69 m, largely influenced by reduced vaccine product sales and increased project development and raw material procurement.

The company recognized asset impairment provisions of RMB 76.91 m and wrote back RMB 62.02 m, resulting in a net reduction of profit by RMB 14.88 m for the period. Additionally, Walvax approved new credit lines for its subsidiaries, Yuxi Walvax and Yuxi Zerun, totaling RMB 620 m from financial institutions for R&D, production, sales, and daily operations, with a one-year term and no collateral required. These financing efforts aim to support operational growth and optimize capital efficiency.